oxycodone deterx® (xtampza™ er [oxycodone extended-release]; herein “deterx (Collegium Pharmaceutical)
90
Structured Review
Collegium Pharmaceutical
oxycodone deterx® (xtampza™ er [oxycodone extended-release]; herein “deterx
Oxycodone Deterx® (Xtampza™ Er [Oxycodone Extended Release]; Herein “Deterx, supplied by Collegium Pharmaceutical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/oxycodone/oxycodone+deterx/pmc04894244-96-7-8
Average 90 stars, based on 1 article reviews
Oxycodone Deterx® (Xtampza™ Er [Oxycodone Extended Release]; Herein “Deterx, supplied by Collegium Pharmaceutical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/oxycodone/oxycodone+deterx/pmc04894244-96-7-8
Average 90 stars, based on 1 article reviews
oxycodone deterx® (xtampza™ er [oxycodone extended-release]; herein “deterx - by Bioz Stars,
2026-09
90/100 stars
Images
1) Product Images from "A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone"
Article Title: A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone
Journal: Pain Medicine: The Official Journal of the American Academy of Pain Medicine
doi: 10.1093/pm/pnv020
Figure Legend Snippet: Summary statistics: oxycodone PK parameters
Techniques Used:
Figure Legend Snippet: Mean plasma oxycodone concentration (ng/mL) over time (hours) for crushed DETERx IN, intact DETERx PO, and crushed OXY-IR IN recorded at multiple time points following administration of study drug. Error bars = ±Standard Deviation. hrs =hours; IN = intranasal; mL = milliliter; ng = nanogram; OXY = oxycodone; OXY-IR = immediate-release oxycodone; PO = per os.
Techniques Used: Concentration Assay, Standard Deviation
Figure Legend Snippet: Mean VAS scores for (a) Drug Liking (bipolar VAS), (b) Drug High (unipolar VAS), and (c) Good Effects (unipolar VAS) during the Double-blind Treatment Phase (N = 36). Each graph shows arithmetic mean VAS results observed during 24 hours for the four treatment conditions: A (●) = crushed DETERx IN; B (□) = intact DETERx PO; C (▵)= crushed OXY-IR IN; D (○) = Placebo. Higher scores denote greater response on the respective PD drug-attractiveness variable; error bars are omitted for clarity purposes. DEQ = drug effects questionnaire; IN = intranasal; mm = millimeter; N = number of observations; OXY = oxycodone; OXY-IR = immediate-release oxycodone; PD = pharmacodynamic; PO = per os; VAS = visual analog scale.
Techniques Used:
Figure Legend Snippet: Cumulative plot of percent reduction in Drug Liking E max for DETERx IN relative to OXY-IR IN in the Double-blind Treatment Phase (N = 36). The vertical Y-axis represents the percent of subjects attaining a percent reduction of Drug Liking for DETERx IN vs OXY-IR IN equal to or greater than the value on the horizontal X-axis. ‘> =’ symbol = greater than or equal to; E max = peak effect; IN = intranasal; IR = immediate-release; N = number of observations; OXY = oxycodone.
Techniques Used:
Figure Legend Snippet: Arithmetic mean results of pupillometry measures during the Double-blind Treatment Phase, encompassing 8 hours of observation in study subjects (N = 36). Treatments: A (●) = crushed DETERx IN; B (□) = intact DETERx PO; C (▵)= crushed OXY-IR IN; D (○) = Placebo. Larger decreases indicate more pupil constriction denoting a greater drug effect; error bars are omitted for clarity purposes. IN = intranasal; IR = immediate-release; mm = millimeter; N = number of observations; OXY = oxycodone; PO = per os.
Techniques Used:
Related Articles
Formulation:Article Title: Patients with chronic pain and dysphagia (CPD): unmet medical needs and pharmacologic treatment options. Article Snippet: Background: For properly selected patients experiencing chronic pain, extended-release opioid formulations may represent an appropriate pain management choice.. For the many adults, elderly, and children who have medical conditions that make swallowing solid, oral-dose formulations difficult (dysphagia) or painful (odynophagia), this option may be limited.. The combination of chronic pain with dysphagia (CPD) presents a challenge to physicians and patients alike when oral opioid analgesia is needed to control pain, but patients are unable to swallow solid, oral dosage forms. Article Title: Oxycodone DETERx ® : A Novel Abuse-Deterrent, Extended-Release Analgesic Option for the Treatment of Patients with Chronic Pain Article Snippet: .. Article Title: A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone Article Snippet: .. Dispersion:Article Title: Patients with chronic pain and dysphagia (CPD): unmet medical needs and pharmacologic treatment options. Article Snippet: Background: For properly selected patients experiencing chronic pain, extended-release opioid formulations may represent an appropriate pain management choice.. For the many adults, elderly, and children who have medical conditions that make swallowing solid, oral-dose formulations difficult (dysphagia) or painful (odynophagia), this option may be limited.. The combination of chronic pain with dysphagia (CPD) presents a challenge to physicians and patients alike when oral opioid analgesia is needed to control pain, but patients are unable to swallow solid, oral dosage forms. Dissolution:Article Title: Evaluation of an Extended-Release, Abuse-Deterrent, Microsphere-in-Capsule Analgesic for the Management of Patients with Chronic Pain With Dysphagia (CPD). Article Snippet: Background: Patients who have chronic pain with dysphagia (difficulty swallowing) (CPD) often have difficulty taking oral medication and, as such, alter their medications by crushing or chewing in an attempt to make it easier to swallow.. Such manipulation of currently marketed, extended-release (ER) opioid analgesics can significantly alter the pharmacokinetic (PK) properties of the formulations, resulting in poor treatment outcome or serious adverse events.. There is an unmet medical need for oral ER opioid formulations suitable for patients with CPD. other:Article Title: Current approaches in tamper-resistant and abuse-deterrent formulations. Article Snippet: Context: The escalating abuse of prescription drugs has recently spawned the development of novel drug formulations resistant to various methods of tampering and misuse.. Objective: The intent of this paper is to provide an overview and classification system of formulation approaches, developed to produce what most refer to as abuse-deterrent or tamper-resistant dosage forms.. Methods: A comprehensive literature search was conducted within EmbaseTM and Medline using key words “abuse deterrent” and “tamper resistant” to identify relevant technologies. |